MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for administering active ingredients in nano micelles by the oral route, Aonys®, announces its participation in the second RNA Leaders Europe congress which is taking place in Basel on 15 and next March 16.
Medesis Pharma teams will be present at this congress to meet key players in the RNA field and discuss the latest advances in RNA chemistry, clinical updates and potential collaborations in the development of RNA-based therapies. of RNA.
On this occasion, they will present a scientific poster: Aonys® technology – Buccal administration for the systemic administration of siRNA describing pharmacokinetic and pharmacology data supporting the potential of the Aonys® drug delivery technology to deliver siRNAs after buccal administration. unmodified for the treatment of neurodegenerative diseases, in particular its potential application in the genetic treatment of Huntington’s disease as well as in oncology to inhibit the expression of an abnormal or overexpressed gene.